GSK (NYSE:GSK – Get Free Report) and Palisade Bio (NASDAQ:PALI – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.
Analyst Recommendations
This is a breakdown of current ratings and price targets for GSK and Palisade Bio, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GSK | 3 | 12 | 4 | 0 | 2.05 |
| Palisade Bio | 1 | 0 | 8 | 2 | 3.00 |
GSK currently has a consensus price target of $55.33, indicating a potential upside of 8.28%. Palisade Bio has a consensus price target of $9.29, indicating a potential upside of 654.94%. Given Palisade Bio’s stronger consensus rating and higher possible upside, analysts plainly believe Palisade Bio is more favorable than GSK.
Earnings and Valuation
This table compares GSK and Palisade Bio”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GSK | $43.07 billion | 2.40 | $7.54 billion | $3.20 | 15.97 |
| Palisade Bio | $250,000.00 | 857.41 | -$16.78 million | ($0.48) | -2.56 |
GSK has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares GSK and Palisade Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GSK | 14.56% | 43.23% | 11.60% |
| Palisade Bio | N/A | -33.47% | -31.79% |
Risk and Volatility
GSK has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Comparatively, Palisade Bio has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.
Institutional and Insider Ownership
15.7% of GSK shares are owned by institutional investors. Comparatively, 11.8% of Palisade Bio shares are owned by institutional investors. 10.0% of GSK shares are owned by insiders. Comparatively, 0.1% of Palisade Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
GSK beats Palisade Bio on 9 of the 15 factors compared between the two stocks.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
About Palisade Bio
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
